Tabulated list of adverse reactions: Table 2 shows the adverse reactions ranked under headings of system organ class and frequency using the following convention: very common, common, uncommon, rare, very rare, not known for NVAF and VTEt respectively. (See Table 2.)

The use of apixaban may be associated with an increased risk of occult or overt bleeding from any tissue or organ, which may result in posthaemorrhagic anaemia. The signs, symptoms, and severity will vary according to the location and degree or extent of the bleeding (see Precautions and Pharmacology: Pharmacodynamics under Actions).
View ADR Reporting Link